B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari et al., Treatment of multiple myeloma, Blood, vol.103, issue.1, pp.20-32, 2004.
DOI : 10.1182/blood-2003-04-1045

URL : https://hal.archives-ouvertes.fr/inserm-00368414

M. H. Bakkus, Y. Bouko, D. Samson, J. F. Apperley, K. Thielemans et al., Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma, British Journal of Haematology, vol.96, issue.2, pp.665-674, 2004.
DOI : 10.1046/j.1365-2141.1998.01075.x

K. Tarte, X. G. Zhang, E. Legouffe, C. Hertog, M. Mehtali et al., Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells, J Immunol, vol.163, pp.514-524, 1999.

C. Pellat-deceunynck, G. Jego, J. L. Harousseau, H. Vie, and R. Bataille, Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells, Clin Cancer Res, vol.5, pp.705-709, 1999.

M. V. Dhodapkar, J. Krasovsky, and K. Olson, T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells, Proceedings of the National Academy of Sciences, vol.99, issue.20, pp.13009-13013, 2002.
DOI : 10.1073/pnas.202491499

K. Noonan, W. Matsui, P. Serafini, R. Carbley, G. Tan et al., Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors, Cancer Research, vol.65, issue.5, pp.2026-2034, 2005.
DOI : 10.1158/0008-5472.CAN-04-3337

G. Tricot, D. H. Vesole, S. Jagannath, J. Hilton, N. Munshi et al., Graftversus-myeloma effect: proof of principle, Blood, vol.87, pp.1196-1198, 1996.

D. G. Maloney, A. J. Molina, F. Sahebi, K. E. Stockerl-goldstein, B. M. Sandmaier et al., Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma, Blood, vol.102, issue.9, pp.3447-3454, 2003.
DOI : 10.1182/blood-2002-09-2955

N. Kroger, A. Shimoni, M. Zagrivnaja, F. Ayuk, M. Lioznov et al., Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma, Blood, vol.104, issue.10, pp.3361-3363, 2004.
DOI : 10.1182/blood-2004-05-2031

V. L. Reichardt, C. Milazzo, W. Brugger, H. Einsele, L. Kanz et al., Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells, Haematologica, vol.88, pp.1139-1149, 2003.

Q. Yi, M. Coscia, S. Mariani, S. Battaglio, C. D. Bello et al., Dendritic Cell-based Immunotherapy in Multiple Myeloma, Leukemia & Lymphoma, vol.100, issue.12, pp.2031-2038, 2003.
DOI : 10.1016/S0145-2126(02)00002-4

S. A. Hurvitz and J. M. Timmerman, Current status of therapeutic vaccines for non-Hodgkin??s lymphoma, Current Opinion in Oncology, vol.17, issue.5, pp.432-440, 2005.
DOI : 10.1097/01.cco.0000174040.52427.83

B. B. Bogen and T. Boon, Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma Tumor antigens recognized by T lymphocytes, Eur J Immunol. Int J Clin Lab Res, vol.26, issue.27, pp.2671-2679, 1996.

P. Van-der-bruggen, Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli et al., Tumor-specific shared antigenic peptides recognized by human T cells, Immunological Reviews, vol.164, issue.1, pp.51-64, 1999.
DOI : 10.1002/(SICI)1521-4141(199902)29:02<602::AID-IMMU602>3.0.CO;2-Y

A. J. Simpson, O. L. Caballero, A. Jungbluth, Y. T. Chen, and L. J. Old, Cancer/testis antigens, gametogenesis and cancer, Nature Reviews Cancer, vol.62, issue.8, pp.615-625, 2005.
DOI : 10.1111/j.1432-1033.1996.t01-1-00827.x

M. J. Scanlan, A. J. Simpson, L. J. Old, Z. , Y. Zhang et al., The cancer/testis genes: review, standardization, and commentary The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies, Cancer Immun. Clin Cancer Res, vol.4, issue.10, pp.6544-6550, 2004.

M. Monji, T. Nakatsura, S. Senju, Y. Yoshitake, M. Sawatsubashi et al., Identification of a Novel Human Cancer/Testis Antigen, KM-HN-1, Recognized by Cellular and Humoral Immune Responses, Clinical Cancer Research, vol.10, issue.18, pp.6047-6057, 2004.
DOI : 10.1158/1078-0432.CCR-04-0475

Y. T. Chen, M. J. Scanlan, C. A. Venditti, R. Chua, G. Theiler et al., Identification of cancer/testis-antigen genes by massively parallel signature sequencing, Moingeon, J. Tartaglia, P. van der Bruggen, P. G. Coulie, and T. Boon, pp.7940-7945, 2005.
DOI : 10.1073/pnas.0502583102

B. Gaugler, B. Van-den-eynde, P. Van-der-bruggen, P. Romero, J. J. Gaforio et al., Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes, Journal of Experimental Medicine, vol.179, issue.3, pp.921-930, 1994.
DOI : 10.1084/jem.179.3.921

E. Stockert, E. Jager, Y. T. Chen, M. J. Scanlan, I. Gout et al., A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens, The Journal of Experimental Medicine, vol.154, issue.8, pp.1349-1354, 1998.
DOI : 10.1097/00008390-199612000-00003

F. Korangy, L. A. Ormandy, J. S. Bleck, J. Klempnauer, L. Wilkens et al., Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma, Clinical Cancer Research, vol.10, issue.13, pp.4332-4341, 2004.
DOI : 10.1158/1078-0432.CCR-04-0181

O. Goodyear, K. Piper, N. Khan, J. Starczynski, P. Mahendra et al., CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden, Blood, vol.106, issue.13, pp.4217-4224, 2005.
DOI : 10.1182/blood-2005-02-0563

K. Tarte, F. Zhan, J. De-vos, B. Klein, J. Shaughnessy et al., Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation, Blood, vol.102, issue.2, pp.592-600, 2003.
DOI : 10.1182/blood-2002-10-3161

L. Intini, L. Nobili, G. Cro, V. Pruneri, C. Callea et al., Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses, Oncogene. Blood, vol.24, issue.105, pp.2461-2473, 2005.

A. A. Jungbluth, S. Ely, M. Diliberto, R. Niesvizky, B. Williamson et al., The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation, Blood, vol.106, issue.1, pp.167-174, 2005.
DOI : 10.1182/blood-2004-12-4931

B. Bataille and . Klein, Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994.

C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes et al., A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma, Blood, vol.91, pp.4727-4737, 1998.

Z. J. Gu, J. De-vos, C. Rebouissou, M. Jourdan, X. G. Zhang et al., Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-197, 2000.
DOI : 10.1038/sj.leu.2401632

J. Rossi, J. Shaughnessy, T. F. Orntoft, and B. Klein, Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts, Blood, vol.100, pp.1113-1122, 2002.

M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, Cluster analysis and display of genome-wide expression patterns, Proceedings of the National Academy of Sciences, vol.95, issue.25, pp.14863-14868, 1998.
DOI : 10.1073/pnas.95.25.14863

A. I. Su, T. Wiltshire, S. Batalov, H. Lapp, K. A. Ching et al., A gene atlas of the mouse and human protein-encoding transcriptomes, Proceedings of the National Academy of Sciences, vol.101, issue.16, pp.6062-6067, 2004.
DOI : 10.1073/pnas.0400782101

B. Rossi, K. Klein, M. V. Tarte, K. Osman, J. Teruya-feldstein et al., Expression of cancer/testis (CT) CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease, Genes encoding tumor-specific antigens are expressed in human myeloma cells, pp.3148-3157, 1999.

C. Pellat-deceunynck, Tumour-associated antigens in multiple myeloma, Br J Haematol, vol.120, pp.3-9, 2003.

Z. Wang, Y. Zhang, H. Liu, E. Salati, M. Chiriva-internati et al., Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies, Blood, vol.101, issue.3, pp.955-960, 2003.
DOI : 10.1182/blood-2002-06-1930

B. J. Taylor, T. Reiman, J. A. Pittman, J. J. Keats, D. R. De-bruijn et al., SSX Cancer Testis Antigens are Expressed in Most Multiple Myeloma Patients, Journal of Immunotherapy, vol.28, issue.6, pp.564-575, 2005.
DOI : 10.1097/01.cji.0000175685.36239.e5

E. Jager, Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer et al., Simultaneous Humoral and Cellular Immune Response against Cancer???Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2???binding Peptide Epitopes, The Journal of Experimental Medicine, vol.157, issue.2, pp.265-270, 1998.
DOI : 10.1097/00008390-199612000-00003

D. Valmori, V. Dutoit, D. Lienard, D. Rimoldi, M. J. Pittet et al., Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients, Cancer Res, vol.60, pp.4499-4506, 2000.

M. Chiriva-internati, Z. Wang, E. Salati, K. Bumm, B. Barlogie et al., Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma, Blood, vol.100, issue.3, pp.961-965, 2002.
DOI : 10.1182/blood-2002-02-0408

R. A. Kyle, T. M. Therneau, S. V. Rajkumar, J. R. Offord, D. R. Larson et al., A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.346, issue.8, pp.564-569, 2002.
DOI : 10.1056/NEJMoa01133202

M. V. Dhodapkar, J. Krasovsky, K. Osman, and M. D. Geller, Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy, The Journal of Experimental Medicine, vol.147, issue.11, pp.1753-1757, 2003.
DOI : 10.1016/S0952-7915(02)00317-5

S. B. Baylin and J. G. Herman, DNA hypermethylation in tumorigenesis: epigenetics joins genetics, Trends in Genetics, vol.16, issue.4, pp.168-174, 2000.
DOI : 10.1016/S0168-9525(99)01971-X

F. Wischnewski, K. Pantel, and H. Schwarzenbach, Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells, Molecular Cancer Research, vol.4, issue.5, pp.339-349, 2006.
DOI : 10.1158/1541-7786.MCR-05-0229

A. O. Gure, R. Chua, B. Williamson, M. Gonen, C. A. Ferrera et al., Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.11, issue.22, pp.8055-8062, 2005.
DOI : 10.1158/1078-0432.CCR-05-1203

N. Yoshida, H. Abe, T. Ohkuri, D. Wakita, M. Sato et al., Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance, International Journal of Oncology, vol.28, pp.1089-1098, 2006.
DOI : 10.3892/ijo.28.5.1089

J. Kim, H. A. Reber, O. J. Hines, K. K. Kazanjian, A. Tran et al., The clinical significance ofMAGEA3 expression in pancreatic cancer, International Journal of Cancer, vol.55, issue.9, pp.2269-2275, 2006.
DOI : 10.1002/ijc.21656

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu et al., Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes, Science, vol.298, issue.5594, pp.850-854, 2002.
DOI : 10.1126/science.1076514

L. Gattinoni, S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer et al., T cells, The Journal of Experimental Medicine, vol.163, issue.7, pp.907-912, 2005.
DOI : 10.4049/jimmunol.173.12.7209

A. P. Rapoport, E. A. Stadtmauer, N. Aqui, A. Badros, J. Cotte et al., Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer, Nature Medicine, vol.104, issue.11, pp.1230-1237, 2005.
DOI : 10.1046/j.1365-2141.1998.00930.x

D. Atanackovic, J. Arfsten, Y. Cao, S. Gnjatic, F. Schnieders et al., Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. Oct 5 Epub ahead of print Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor, Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients. In ASH, pp.356-59, 2006.

C. Choi, M. Witzens, M. Bucur, M. Feuerer, N. Sommerfeldt et al., Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma, Blood, vol.105, issue.5, pp.2132-2134, 2005.
DOI : 10.1182/blood-2004-01-0366

M. Hundemer, S. Schmidt, M. Condomines, A. Lupu, D. Hose et al., Identification of a new HLA-A2???restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma, Experimental Hematology, vol.34, issue.4, pp.486-496, 2006.
DOI : 10.1016/j.exphem.2006.01.008

URL : https://hal.archives-ouvertes.fr/inserm-00131759